This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
by Ekta Bagri
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
by Kanishka Das
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
AMRXPositive Net Change TEVAPositive Net Change NBIXPositive Net Change
biotechs
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
by Zacks Equity Research
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
ALKSNegative Net Change RGENNegative Net Change LQDAPositive Net Change
biotechs
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
by Zacks Equity Research
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
TNGXNegative Net Change RGENNegative Net Change AMRNNegative Net Change LQDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
by Zacks Equity Research
RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
RCKTPositive Net Change RGENNegative Net Change LQDAPositive Net Change
biotechs earnings
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
by Zacks Equity Research
AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
AXSMNo Net Change JAZZNegative Net Change RGENNegative Net Change LQDAPositive Net Change
biotechs earnings
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
by Sundeep Ganoria
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
ABBVNegative Net Change JNJNegative Net Change LLYNegative Net Change
biotechs earnings medical pharmaceuticals
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
by Zacks Equity Research
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
BBIONegative Net Change PFENegative Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs earnings medical
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
by Zacks Equity Research
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
KODPositive Net Change ALTPositive Net Change AMRXPositive Net Change LQDAPositive Net Change
biotechnology biotechs